Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database

This analysis represents one of the largest and longest post-marketing pharmacovigilance evaluations of an individual IVIg product. Findings demonstrate stable long-term safety and an ADR profile consistent with clinical trial data and approved product labeling, supporting a favorable benefit-risk profile.